Back to today’s briefing

Story perspectives

FDA Recalls 580,000 Prazosin Capsules Over Cancer Risk

10/28/2025

50 9

Summary

Story summary

The U.S. Food and Drug Administration (FDA) issued a recall for over 580,000 bottles of Prazosin Hydrochloride Capsules (1 mg and 2 mg) due to nitrosamine impurities that could cause cancer with prolonged high-dose use.
The recall is Class II, indicating a low probability of serious health consequences.
Patients should not stop their medications abruptly and should consult healthcare professionals about treatment options.

1 of 1

Story summary

The U.S. Food and Drug Administration (FDA) issued a recall for over 580,000 bottles of Prazosin Hydrochloride Capsules (1 mg and 2 mg) due to nitrosamine impurities that could cause cancer with prolonged high-dose use.
The recall is Class II, indicating a low probability of serious health consequences.
Patients should not stop their medications abruptly and should consult healthcare professionals about treatment options.